Related Experiment Video
Updated: Aug 17, 2026

An Ex vivo Assay to Study Candida albicans Hyphal Morphogenesis in the Gastrointestinal Tract
Published on: July 1, 2020
New agents for the treatment of systemic fungal infections--current status
1Department of Microbiology and Clinical Microbiology, Hacettepe University Medical School, 06100 Ankara, Turkey. sarikan@metu.edu.tr
Abstract:
Systemic antifungal chemotherapy is enjoying its most dynamic era. More antifungal agents are under development than ever before, including agents in entirely new classes. Major goals of current investigations are to identify compounds with a wide spectrum of activity, minimal toxicity and a high degree of target specificity. The antifungal drugs in development include new azoles {voriconazole, posaconazole (formerly SCH-56592), ravuconazole (formerly BMS-207147)}, lipid formulations of amphotericin B, a lipid formulation of nystatin, echinocandins {anidulafungin (formerly, LY-303366, VER-002), caspofungin (formerly MK-991), micafungin (formerly FK-463)}, antifungal peptides other than echinocandins, and sordarin derivatives. This discussion reviews the currently available antifungal agents and summarises the developmental issues that surround these new systemic antifungal drugs.
Related Concept Videos
Antifungal Agents
Antiprotozoal Agents
Cryptococcal Meningitis
Anthelminthic Agents
Fungal Phylum Microsporidia
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
